Clinical efficacy of &gamma;‑globulin combined with dexamethasone and methylprednisolone, respectively, in the treatment of acute transverse myelitis and its effects on immune function and quality of life

Wang,Peiquan; Zhang,Suhua; Lv,Hongchun; Qiao,Gang; Zhong,Xiaodong; Li,Hua; Zhang,Lili

doi:10.3892/etm.2020.9234

Clinical efficacy of γ‑globulin combined with dexamethasone and methylprednisolone, respectively, in the treatment of acute transverse myelitis and its effects on immune function and quality of life

Authors:
- Peiquan Wang
- Suhua Zhang
- Hongchun Lv
- Gang Qiao
- Xiaodong Zhong
- Hua Li
- Lili Zhang
View Affiliations

Affiliations: Department of Critical Care Medicine, Linzi District People's Hospital, Zibo, Shandong 255400, P.R. China
Published online on: September 18, 2020 https://doi.org/10.3892/etm.2020.9234
Article Number: 104
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Effects of γ‑globulin combined with dexamethasone or methylprednisolone in the treatment of acute transverse myelitis (ATM) were investigated. A retrospective analysis of medical records from 136 ATM patients admitted to Linzi District People's Hospital from July 2014 to September 2017 was performed. Patients treated with dexamethasone combined with γ‑globulin were in group A (66 cases), and patients treated with methylprednisolone combined with γ‑globulin were in group B (70 cases). Clinical efficacy, recovery time of bone marrow function and incidence rate of adverse reactions were analyzed and compared between the two groups. T‑lymphocyte subsets in peripheral blood of both groups were detected by Flow cytometry. Quality of life of patients was assessed by the Quality of Life Scale (SF‑36) developed by the American Institute of Medicine. Time of sensory recovery, self‑walking, improving muscle strength at two levels and urination recovery after treatment in group B were significantly shorter than those in group A (P<0.001); effective rate of treatment in group B was significantly higher than that in group A (P<0.05); incidence rate of adverse reactions in group B was significantly lower than that in group A (P<0.05); ratios of CD3⁺, CD4⁺, CD8⁺ cells and CD4⁺/CD8⁺ in peripheral blood of group A and group B after treatment were significantly higher than those before treatment (P<0.05); scores of general health (GH), physical function (PF), role physical (RP), body pain (BP), social function (SF), role emotional (RE), mental health (MH) and vitality (VT) in group B after treatment were significantly higher than those in group A (P<0.05). In conclusion, clinical efficacy of γ‑globulin combined with methylprednisolone in the treatment of ATM patients shows definitely fewer adverse reactions, which can improve their immune function and quality of life.

View Figures

View References

1	He H, Jin L, Ju M, Tu G and Luo Z: Acute transverse myelitis of the cervical spine secondary to psoas abscess. BMC Infect Dis. 16(579)2016.PubMed/NCBI View Article : Google Scholar
2	Frohman EM and Wingerchuk DM: Clinical practice. Transverse myelitis. N Engl J Med. 363:564–572. 2010.PubMed/NCBI View Article : Google Scholar
3	The Lancet Infectious Diseases: Enterovirus D68: The unexpected guest. Lancet Infect Dis 14: 1023, 2014.
4	Holm-Hansen CC, Midgley SE and Fischer TK: Global emergence of enterovirus D68: A systematic review. Lancet Infect Dis. 16:e64–e75. 2016.PubMed/NCBI View Article : Google Scholar
5	Huh Y, Park EJ, Jung JW, Oh S and Choi SC: Clinical insights for early detection of acute transverse myelitis in the emergency department. Clin Exp Emerg Med. 2:44–50. 2015.PubMed/NCBI View Article : Google Scholar
6	Chen L, Li J, Guo Z, Liao S and Jiang L: Prognostic indicators of acute transverse myelitis in 39 children. Pediatr Neurol. 49:397–400. 2013.PubMed/NCBI View Article : Google Scholar
7	Kuo SC, Cho WH, Shih HI and Tu YF: Idiopathic acute transverse myelitis in children: A retrospective series. Neuropediatrics. 46:307–312. 2015.PubMed/NCBI View Article : Google Scholar
8	Li J, Zhou J and Zhan QS: Comparative observation of Methylprednisolone and gamma globulin in the treatment of acute myelitis. Chin J Biochem Pharm. 37:163–164. 2017.
9	Nelson GR, Bonkowsky JL, Doll E, Green M, Hedlund GL, Moore KR and Bale JF Jr: Recognition and management of acute flaccid myelitis in children. Pediatr Neurol. 55:17–21. 2016.PubMed/NCBI View Article : Google Scholar
10	Branch DR: Serologic problems associated with administration of intravenous immune globulin (IVIg). Immunohematology. 35:13–15. 2019.PubMed/NCBI
11	Greenberg BM and Frohman EM: Immune-mediated myelopathies. Continuum (Minneap Minn). 21 (1 Spinal Cord Disorders):121–131. 2015.PubMed/NCBI View Article : Google Scholar
12	Patel V, Griffith NC, Blackwood E, Dias M and Cordato DJ: Spectrum disorder of neuromyelitis optica in a patient presenting with intractable vomiting and hiccups, transverse myelitis and acute encephalopathy. J Clin Neurosci. 19:1576–1578. 2012.PubMed/NCBI View Article : Google Scholar
13	Hurlbert RJ: Methylprednisolone for the treatment of acute spinal cord injury: Point. Neurosurgery. 61 (Suppl 1):32–35. 2014.PubMed/NCBI View Article : Google Scholar
14	Torisu H, Kira R, Ishizaki Y, Sanefuji M, Yamaguchi Y, Yasumoto S, Murakami Y, Shimono M, Nagamitsu S, Masuzaki M, et al: Clinical study of childhood acute disseminated encephalomyelitis, multiple sclerosis, and acute transverse myelitis in Fukuoka Prefecture, Japan. Brain Dev. 32:454–462. 2010.PubMed/NCBI View Article : Google Scholar
15	West TW: Transverse myelitis - a review of the presentation, diagnosis, and initial management. Discov Med. 16:167–177. 2013.PubMed/NCBI
16	Yarlas A, Bayliss M, Cappelleri JC, Maher S, Bushmakin AG, Chen LA, Manuchehri A and Healey P: Psychometric validation of the SF-36^® Health Survey in ulcerative colitis: Results from a systematic literature review. Qual Life Res. 27:273–290. 2018.PubMed/NCBI View Article : Google Scholar
17	Annunziata P, Masi G, Cioni C, Gastaldi M, Marchioni E, D'amico E, Patti F, Laroni A, Mancardi G, Vitetta F, et al: Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: An Italian multicenter study. Neurol Sci. 40:1383–1391. 2019.PubMed/NCBI View Article : Google Scholar
18	West TW, Hess C and Cree BAC: Acute transverse myelitis: Demyelinating, inflammatory, and infectious myelopathies. Semin Neurol. 32:97–113. 2012.PubMed/NCBI View Article : Google Scholar
19	Dhandha MM, Siegfried EC and Knutsen AP: Treatment of selective antibody deficiency with IVIG resulting in decreased frequency of streptococcal infection and improvement of guttate psoriasis. Dermatol Online J. 23(23)2017.PubMed/NCBI
20	Tomietto P, D'Agostini S, Annese V, De Vita S and Ferraccioli G: Mycophenolate mofetil and intravenous dexamethasone in the treatment of persistent lupus myelitis. J Rheumatol. 34:588–591. 2007.PubMed/NCBI
21	Costa DD, Beghi E, Carignano P, Pagliacci C, Faccioli F, Pupillo E, Messina P, Gorio A and Redaelli T: Tolerability and efficacy of erythropoietin (EPO) treatment in traumatic spinal cord injury: A preliminary randomized comparative trial vs. methylprednisolone (MP). Neurol Sci. 36:1567–1574. 2015.PubMed/NCBI View Article : Google Scholar
22	Defresne P, Meyer L, Tardieu M, Scalais E, Nuttin C, De Bont B, Loftus G, Landrieu P, Kadhim H and Sébire G: Efficacy of high dose steroid therapy in children with severe acute transverse myelitis. J Neurol Neurosurg Psychiatry. 71:272–274. 2001.PubMed/NCBI View Article : Google Scholar
23	Kovacs B, Lafferty TL, Brent LH and DeHoratius RJ: Transverse myelopathy in systemic lupus erythematosus: An analysis of 14 cases and review of the literature. Ann Rheum Dis. 59:120–124. 2000.PubMed/NCBI View Article : Google Scholar
24	Pavlou E, Gkampeta A, Kouskouras K, Evangeliou A and Athanasiadou-Piperopoulou F: Idiopathic acute transverse myelitis: Complete recovery after intravenous immunoglobulin. Hippokratia. 16:283–285. 2012.PubMed/NCBI
25	den Otter I, Willems LN, van Schadewijk A, van Wijngaarden S, Janssen K, de Jeu RC, Sont JK, Sterk PJ and Hiemstra PS: Lung function decline in asthma patients with elevated bronchial CD8, CD4 and CD3 cells. Eur Respir J. 48:393–402. 2016.PubMed/NCBI View Article : Google Scholar
26	Zhao Z, Liao H and Ju Y: Effect of compound Kushen injection on T-cell subgroups and natural killer cells in patients with locally advanced non-small-cell lung cancer treated with concomitant radiochemotherapy. J Tradit Chin Med. 36:14–18. 2016.PubMed/NCBI View Article : Google Scholar
27	Larroche C, Chanseaud Y, Garcia de la Pena-Lefebvre P and Mouthon L: Mechanisms of intravenous immunoglobulin action in the treatment of autoimmune disorders. BioDrugs. 16:47–55. 2002.PubMed/NCBI View Article : Google Scholar
28	Ballow M: The IgG molecule as a biological immune response modifier: Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol. 127:315–323; quiz 324-325. 2011.PubMed/NCBI View Article : Google Scholar
29	Esposito E, Bruscoli S, Mazzon E, Paterniti I, Coppo M, Velardi E, Cuzzocrea S and Riccardi C: Glucocorticoid-induced leucine zipper (GILZ) over-expression in T lymphocytes inhibits inflammation and tissue damage in spinal cord injury. Neurotherapeutics. 9:210–225. 2012.PubMed/NCBI View Article : Google Scholar
30	Gelfand EW: Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 367:2015–2025. 2012.PubMed/NCBI View Article : Google Scholar